Skip to content
Pharma Observatory a Scientist.com platform
  • Trial site

Trial site location from the registry's own city and country. GeoNames (geonames.org).

Clinical trial site

University of Chicago

University of Chicago in Chicago, Illinois, United States is listed as a site for 1,291 registered clinical trials, 326 of them ongoing.

Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Registered trials 1,291
Ongoing 326

This page covers the site record University of Chicago in Chicago, Illinois, United States: the trials that list it by this name in ClinicalTrials.gov. The same place can be registered under other names, each with its own page and its own trials, and a count here is a number of registered trials, not of patients enrolled. The organization of the same name, University of Chicago, also sponsors trials.

Get the University of Chicago report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Trials by phase

Registered trials that list this site, by trial phase. 1,291 trials counted.

  • Phase 1 152 trials
  • Phase 1/2 103 trials
  • Phase 2 316 trials
  • Phase 2/3 36 trials
  • Phase 3 190 trials
  • Phase 4 53 trials
  • Not applicable 257 trials
  • Observational 177 trials
  • Expanded access 7 trials

Trials by status

The registry's own status summary: Ongoing, Completed, Terminated or Other.

  • Ongoing 327 trials
  • Completed 720 trials
  • Terminated 209 trials
  • Other 35 trials

Trials over time

Trials registered with a start date in each year, 1990 onward, most recent years first.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 76

1994: 1 trials (Phase 3 1) 1995: 1 trials (Observational 1) 1996: 1 trials (Observational 1) 1997: 1 trials (Phase 3 1) 1998: 3 trials (Observational 1, Phase 3 1, Phase 2 1) 1999: 4 trials (Not applicable 1, Phase 4 1, Phase 2 1, Phase 1 1) 2000: 5 trials (Other 1, Not applicable 2, Phase 4 1, Phase 3 1) 2001: 6 trials (Not applicable 2, Phase 2/3 1, Phase 2 3) 2002: 16 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 8, Phase 1/2 2) 2003: 23 trials (Observational 5, Not applicable 3, Phase 4 1, Phase 3 2, Phase 2 9, Phase 1/2 2, Phase 1 1) 2004: 22 trials (Phase 3 3, Phase 2 12, Phase 1/2 2, Phase 1 5) 2005: 41 trials (Observational 6, Not applicable 5, Phase 4 2, Phase 3 5, Phase 2/3 3, Phase 2 13, Phase 1/2 1, Phase 1 6) 2006: 49 trials (Observational 5, Not applicable 4, Phase 4 5, Phase 3 8, Phase 2/3 1, Phase 2 20, Phase 1 6) 2007: 45 trials (Observational 3, Not applicable 3, Phase 4 4, Phase 3 8, Phase 2/3 2, Phase 2 18, Phase 1/2 2, Phase 1 5) 2008: 47 trials (Observational 6, Not applicable 9, Phase 4 6, Phase 3 7, Phase 2/3 1, Phase 2 9, Phase 1/2 6, Phase 1 3) 2009: 48 trials (Observational 9, Not applicable 8, Phase 4 4, Phase 3 8, Phase 2/3 1, Phase 2 11, Phase 1/2 1, Phase 1 6) 2010: 53 trials (Observational 10, Not applicable 13, Phase 4 1, Phase 3 9, Phase 2/3 1, Phase 2 15, Phase 1/2 1, Phase 1 3) 2011: 56 trials (Observational 12, Not applicable 11, Phase 4 3, Phase 3 9, Phase 2 14, Phase 1/2 1, Phase 1 6) 2012: 37 trials (Observational 6, Not applicable 4, Phase 3 7, Phase 2/3 2, Phase 2 11, Phase 1/2 3, Phase 1 4) 2013: 52 trials (Observational 6, Not applicable 11, Phase 4 1, Phase 3 5, Phase 2/3 1, Phase 2 20, Phase 1/2 3, Phase 1 5) 2014: 53 trials (Observational 6, Not applicable 11, Phase 4 2, Phase 3 7, Phase 2/3 1, Phase 2 13, Phase 1/2 5, Phase 1 8) 2015: 62 trials (Observational 7, Not applicable 10, Phase 4 1, Phase 3 5, Phase 2/3 1, Phase 2 22, Phase 1/2 7, Phase 1 9) 2016: 57 trials (Observational 9, Not applicable 12, Phase 3 7, Phase 2/3 4, Phase 2 12, Phase 1/2 8, Phase 1 5) 2017: 63 trials (Observational 5, Not applicable 13, Phase 4 1, Phase 3 10, Phase 2/3 1, Phase 2 17, Phase 1/2 5, Phase 1 11) 2018: 76 trials (Observational 11, Not applicable 12, Phase 4 2, Phase 3 12, Phase 2/3 4, Phase 2 20, Phase 1/2 5, Phase 1 10) 2019: 73 trials (Observational 12, Not applicable 15, Phase 4 1, Phase 3 10, Phase 2/3 2, Phase 2 17, Phase 1/2 10, Phase 1 6) 2020: 72 trials (Observational 7, Not applicable 14, Phase 4 4, Phase 3 11, Phase 2/3 3, Phase 2 13, Phase 1/2 2, Phase 1 18) 2021: 60 trials (Observational 11, Not applicable 12, Phase 4 1, Phase 3 9, Phase 2/3 2, Phase 2 10, Phase 1/2 8, Phase 1 7) 2022: 49 trials (Observational 7, Not applicable 12, Phase 4 5, Phase 3 6, Phase 2/3 1, Phase 2 2, Phase 1/2 8, Phase 1 8) 2023: 70 trials (Observational 12, Not applicable 19, Phase 4 4, Phase 3 10, Phase 2/3 2, Phase 2 11, Phase 1/2 6, Phase 1 6) 2024: 52 trials (Observational 7, Not applicable 23, Phase 4 1, Phase 3 6, Phase 1/2 7, Phase 1 8) 2025: 49 trials (Observational 4, Not applicable 17, Phase 4 1, Phase 3 9, Phase 2/3 1, Phase 2 9, Phase 1/2 5, Phase 1 3)

Trials that list this site and are registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 27
2025 49
2024 52
2023 70
2022 49
2021 60
2020 72
2019 73
2018 76
2017 63

2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here

Recent trials

The newest registered trials that list this site. Each title opens its ClinicalTrials.gov record.

Source: ClinicalTrials.gov

Lead sponsors

Most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Conditions studied

The specific conditions of the trials that list this site, most trials first.